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Objectives: The effectiveness of endovascular brachytherapy (EVBT)
for in-stent restenosis (ISR) after percutaneous transluminal angioplasty
(PTA) and stenting (PTAS) has been limited by edge stenosis and late
thrombosis. We evaluated a novel protocol of PTA and EVBT for ISR in
lower extremity occlusive disease.
Methods: We conducted a retrospective, single-center review of
patients treated with PTA and EVBT for ISR in the iliac and femoropopli-
teal segments between 11/2004 and 11/2012. Twenty Gy in a single frac-
tion was prescribed to 0.5 mm beyond the radius of the largest balloon and
with proximal and distal margins of at least 2 cm. Stents were duplexed at 1,
3, 6, 9, 12, and 18 months, and then yearly. The primary endpoint was
freedom from $75% restenosis in the treated segment. Patency data were
estimated using the Kaplan-Meier method.
Results: Forty-two consecutive cases of EVBT for ISR in iliac (24%;
n ¼ 10) and femoropopliteal (38%; n ¼ 32) arteries were performed.
Twenty patients (47.6%) had claudication, ﬁve (11.9%) had critical
limb ischemia, and 17 (40.4%) were asymptomatic. Median time from
stenting to EVBT was 594 days (interquartile range, 324-1124 days).
Thirteen (31%) patients underwent additional stent placement at time
of EVBT. Mean treated length was 23.5 6 12.3 cm over mean duration
of 16.1 6 9.6 minutes. Median post-EVBT follow-up time was 675 days
(interquartile range, 272-967 days). There were two periprocedural and
ﬁve late thrombotic occlusions. There was one death, thought to be
unrelated to EVBT. Post-EVBT patency data are shown in the Fig.
Primary-assisted patency rates for recurrent ISR of $50% were identical
to that of $75%.
Conclusions: EVBT appears to be a promising option for ISR in the
iliac and femoropopliteal arteries, particularly with a strategy of intervening
upon at-risk stents prior to occlusion. Future studies may help delineate
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Introduction: Neointimal hyperplasia is the leading cause of vein
graft failure. Interventions aimed at inhibiting smooth muscle proliferation
have not succeeded in human studies. Eph-B4 induces venous identity, and
its expression is lost during venous adaptation. Previous studies have
demonstrated that exogenous stimulation of Eph-B4 with its ligand Eph-
rin-B2 reduces neointimal hyperplasia during murine vein graft adaptation.However, it is not known whether this pathway is active and can be manip-
ulated in human vein grafts. Thus our objective was to demonstrate that
activation of Eph-B4 with exogenous Ephrin-B2/Fc would reduce neointi-
mal hyperplasia in human saphenous veins in an in vitro model of neointimal
hyperplasia.
Methods: Excess saphenous vein was obtained from patients under-
going bypass surgery. Vein rings were cultured for 14 days with Ephrin-
B2/Fc at concentrations between 0 and 2 ug/mL. Each ring was
compared with its matched control for development of intimal hyperplasia
and quantitative real-time polymerase chain reaction was performed to
assess gene expression. Human umbilical vein endothelial cells were
treated with Ephrin-B2/Fc and receptor phosphorylation was detected
with western blot.
Results: Treatment of vein rings with Ephrin-B2/Fc led to an average
of 30.8% (95% conﬁdence interval, 6.56-55.0; n ¼ 20) decrease in neointi-
mal hyperplasia compared with controls. Eph-B4 and ephrin-B2 expression
signiﬁcantly decreased in organ culture while osteopontin expression
increased (n ¼ 7). Cultured endothelial cells demonstrated a signiﬁcant
increase in Eph-B4 phosphorylation when treated with Ephrin-B2/Fc as
well as increased phosphorylated of downstream signaling proteins AKT
and ERK.
Conclusions: The Eph-B4 signaling pathway is active in human
venous cells and stimulation of Eph-B4 in vitro leads to reduced neoimtimal
hyperplasia in saphenous vein rings. Stimulation of the Eph-B4 pathway may
be a promising candidate for a clinical trial to reduce vein graft neointimal
hyperplasia.
Cost-Effectiveness of Exercise Therapy Versus Primary Stenting for
Patients with Intermittent Claudication and Iliofemoral Disease
Marcus E. Semel, Karen J. Ho, C. Keith Ozaki, Michael Belkin. Brigham
and Women’s Hospital, Boston, Mass
Objectives: Supervised exercise (SE) is an evidence-based treatment
for intermittent claudication (IC). While primary stenting (PS) for iliofe-
moral occlusive disease may improve outcomes over angioplasty alone, it
may do so at increased cost. Although prior reports have failed to show
superiority of angioplasty over SE, we hypothesize that PS is cost-effec-
tive when compared with SE.
